NO20024746L - Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom - Google Patents
Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdomInfo
- Publication number
- NO20024746L NO20024746L NO20024746A NO20024746A NO20024746L NO 20024746 L NO20024746 L NO 20024746L NO 20024746 A NO20024746 A NO 20024746A NO 20024746 A NO20024746 A NO 20024746A NO 20024746 L NO20024746 L NO 20024746L
- Authority
- NO
- Norway
- Prior art keywords
- galantamine
- alzheimer
- disease
- treatment
- behavior associated
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229960003980 galantamine Drugs 0.000 title 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20024746D0 NO20024746D0 (no) | 2002-10-02 |
| NO20024746L true NO20024746L (no) | 2002-11-28 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024746A NO20024746L (no) | 2000-04-03 | 2002-10-02 | Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (no) |
| JP (1) | JP2003528913A (no) |
| KR (1) | KR20020086911A (no) |
| CN (1) | CN1430514A (no) |
| AU (2) | AU2001265844B2 (no) |
| BG (1) | BG107093A (no) |
| BR (1) | BR0109770A (no) |
| CA (1) | CA2310926C (no) |
| CZ (1) | CZ20023543A3 (no) |
| EE (1) | EE200200554A (no) |
| HR (1) | HRP20020778A2 (no) |
| HU (1) | HUP0300566A3 (no) |
| IL (1) | IL152061A0 (no) |
| MX (1) | MXPA02009777A (no) |
| NO (1) | NO20024746L (no) |
| PL (1) | PL361272A1 (no) |
| RU (1) | RU2002129298A (no) |
| SK (1) | SK15422002A3 (no) |
| WO (1) | WO2001074339A2 (no) |
| ZA (1) | ZA200207935B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| AU2004262897B9 (en) * | 2003-07-25 | 2009-12-17 | F. Hoffmann-La Roche Ag | Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| EP4088717A1 (en) | 2008-03-27 | 2022-11-16 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| EE04996B1 (et) * | 1998-12-24 | 2008-04-15 | Janssen Pharmaceutica N.V. | Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Ceased
- 2001-03-28 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Ceased
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0300566A3 (en) | 2004-10-28 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926C (en) | 2002-10-15 |
| BR0109770A (pt) | 2003-02-04 |
| CN1430514A (zh) | 2003-07-16 |
| MXPA02009777A (es) | 2003-03-27 |
| EP1272192A2 (en) | 2003-01-08 |
| AU6584401A (en) | 2001-10-15 |
| JP2003528913A (ja) | 2003-09-30 |
| ZA200207935B (en) | 2004-01-30 |
| IL152061A0 (en) | 2003-05-29 |
| HUP0300566A2 (hu) | 2003-06-28 |
| EE200200554A (et) | 2004-04-15 |
| NO20024746D0 (no) | 2002-10-02 |
| KR20020086911A (ko) | 2002-11-20 |
| BG107093A (bg) | 2003-06-30 |
| AU2001265844B2 (en) | 2005-04-14 |
| RU2002129298A (ru) | 2004-03-27 |
| PL361272A1 (en) | 2004-10-04 |
| WO2001074339A3 (en) | 2002-09-12 |
| CA2310926A1 (en) | 2000-10-04 |
| WO2001074339A2 (en) | 2001-10-11 |
| SK15422002A3 (sk) | 2003-04-01 |
| HRP20020778A2 (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1392287T3 (da) | Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom | |
| CY2020003I2 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
| FI962557A7 (fi) | PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa | |
| IL153214A0 (en) | Compounds to treat alzheimer's disease | |
| EP1267798A4 (en) | Treatment of skin damage using polyenylphosphatidylcholine | |
| NO20022531D0 (no) | Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer | |
| NO20041588L (no) | Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser | |
| NO20025004D0 (no) | Fremgangsmåte for fremstilling av 2,5-diketopiperaziner, 2,5- diketopiperaziner, dipeptider samt anvendelse derav | |
| DK1296705T3 (da) | Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom | |
| AR027945A1 (es) | Uso de pramipexol en el tratamiento de transtornos de adiccion | |
| NO20002686L (no) | Forbedring av Peyronies sykdom | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| FR2812197B1 (fr) | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| NO20024746L (no) | Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom | |
| NO20040659L (no) | Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom | |
| IL172213A0 (en) | Compounds useful in the therapy of alzheimer's disease and formulations containing them | |
| EE200200670A (et) | S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks | |
| MA25509A1 (fr) | Composition destinee au traitement de l'hepatite c | |
| AU2003286530A8 (en) | Substituted peptides useful in the treatment of alzheimer's disease | |
| NO20030762D0 (no) | Forbedret spesifisitet i behandling av sykdommer | |
| DK1152762T3 (da) | Anvendelse af desoxypeganin til behandling af Alzheimers demens | |
| GB0008162D0 (en) | Diagnosis and treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |